

Appendix 3. List of prohibited medications

The concomitant use of drugs listed below may interfere with the assessment of efficacy, safety, or tolerability of the study medicinal products. Therefore, they are prohibited for the patient at randomization or at any time during the entire study period:

- Inducers of hepatic drug metabolism (rifampin, phenytoin, phenobarbital, carbamazepine) or substrates or inhibitors of CYP2D6 such as amiodarone, cimetidine, fluoxetine, paroxetine, quinidine, amitriptyline, etc.
- Any opioid or opioid containing medication such as morphine, oxycodone, fentanyl, buprenorphin, codeine etc.
- All tricyclic antidepressants, selective serotonin reuptake inhibitors, selective norepinephrine reuptake inhibitors, antipsychotics, neuroleptics, anxiolytics, benzodiazepines or benzodiazepines derivatives, psychostimulants, monoamine oxidase inhibitors, sedatives
- Anticonvulsant medications such as pregabalin, valproic acid, etc.
- All NSAIDs with the exception of ibuprofen
- Macrolide antibiotics such as erythromycin, etc. with the exception of azithromycin
- HIV drugs such as ritonavir, etc.
- Azole antifungals such as itraconazole, etc.
- Digoxin
- Vitamin K antagonists such as warfarin, etc.
- Linezolid
- Metamizole
- Systemic (oral or injectable) corticosteroids administered for pain caused by infiltration or compression of neural structures, e.g. peripheral nerves or spinal cord.